Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?, Clinical Lymphoma Myeloma & Leukemia, September 2019, Elsevier,
DOI: 10.1016/j.clml.2019.05.020.
You can read the full text:
Contributors
The following have contributed to this page
